Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2022 07:30 ET | Source: MediWound Ltd.

MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates

Positive Results in Two Phase 2 Trials of EscharEx FDA Assigned PDUFA Target Date of January 1, 2023 for NexoBrid BLA Enhanced the Board and Leadership Team Conference Call Begins Today at 8:30 AM...
August 08, 2022 16:05 ET | Source: MediWound Ltd.

MediWound Enhances Its Board and Executive Leadership Team

Mr. Nachum Shamir appointed as Chairman of the Board Dr. Robert Snyder appointed as Chief Medical Officer YAVNE, Israel, Aug. 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the...
August 03, 2022 07:30 ET | Source: MediWound Ltd.

MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

YAVNE, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
August 01, 2022 08:00 ET | Source: MediWound Ltd.

MediWound Schedules Second Quarter 2022 Financial Results

Call Scheduled for Tuesday, August 9, 2022 at 8:30 AM Eastern Time YAVNE, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company...
July 11, 2022 07:00 ET | Source: MediWound Ltd.

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

MW005 Shown to Be Safe and Well-ToleratedTarget Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel, July 11, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD)...
July 08, 2022 08:00 ET | Source: MediWound Ltd.

MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
July 07, 2022 07:00 ET | Source: MediWound Ltd.

MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUsData Demonstrates EscharEx Reduced Wound Size, Biofilm and Bacterial Burden YAVNE, Israel, July 07, 2022 (GLOBE NEWSWIRE) --...
July 05, 2022 16:05 ET | Source: MediWound Ltd.

MediWound to Host a Key Opinion Leader Investor Day on EscharEx

YAVNE, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
June 30, 2022 07:00 ET | Source: MediWound Ltd.

MediWound Names Mr. Tzvi Palash as Chief Operating Officer

YAVNE, Israel, June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
May 17, 2022 07:01 ET | Source: MediWound Ltd.

MediWound Announces CEO Transition

Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka, who will join the Board of Directors ...